Associate Professor AIIMS BIBINAGAR HYDERABAD, Telangana, India
Objectives : To evaluate the effectiveness and safety of bupivacaine TPIs in trapezius MPS.
Design: A retrospective review of 69 patients with clinically diagnosed trapezius MPS who received 0.25% bupivacaine TPIs was conducted at a tertiary care center (Aug 2023–Feb 2025). Pain intensity (Visual Analog Scale, VAS) and disability (Neck Pain and Disability Index, NPD) were assessed at baseline, immediately post-injection, 2 weeks, and 1 month. Repeated measures ANOVA with post-hoc analysis determined statistical significance.
Results: Mean VAS scores improved significantly from 6.10 at baseline to 2.64 at one month (p < 0.001). Similarly, mean NPD scores decreased from 31.7 to 12.8 (p < 0.001). The majority (94.2%) reported no adverse effects, while minor self-limiting events occurred in 4 patients. Overall, 70.6% expressed satisfaction with the intervention.
Conclusion: Bupivacaine TPIs are effective and safe for pain reduction and functional improvement in trapezius MPS, offering a pragmatic, low-cost treatment option in clinical practice.
